Research and Markets: Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/c67f8b/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering.

2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars.

This growth will be driven by:

- The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab)

- The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab

- Increased access to PsO biologics in China and India

Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other.

Unmet Needs in Psoriasis

While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Opportunity and Unmet Need

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

  • Amgen
  • AbbVie (Abbott)
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Eli Lilly
  • Merck
  • LEO Pharma
  • Celgene

For more information visit http://www.researchandmarkets.com/research/c67f8b/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals